A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT03437083
- Locations
- π°π·
Eisai Trial site_03, Ansan, Korea, Republic of
π°π·Eisai Trial site_02, Seoul, Korea, Republic of
π°π·Eisai Trial site_06, Busan, Korea, Republic of
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
Completed
- Conditions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03264690
- Locations
- π°π·
Eisai Trial Site # 2, Seoul, Korea, Republic of
π°π·Eisai Trial Site # 1, Seoul, Korea, Republic of
π°π·Eisai Trial Site # 3, Seoul, Korea, Republic of
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
Completed
- Conditions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT03264703
- Locations
- π°π·
Eisai Trial Site # 2, Seoul, Korea, Republic of
π°π·Eisai Trial Site # 5, Seoul, Korea, Republic of
π°π·Eisai Trial Site # 8, Seoul, Korea, Republic of
Post-Marketing Surveillance of Lenvima in Korean Patients
Completed
- Conditions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT02764554
- Locations
- π°π·
Eisai Trial Site #19, Jeju, Korea, Republic of
π°π·Eisai Trial Site #24, Yangsan, Gyeongsangnam-do, Korea, Republic of
π°π·Eisai Trial Site #25, Incheon, Korea, Republic of
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT02726074
A Study of Fycompa (Perampanel) in Korean Participants
Completed
- Conditions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 3692
- Registration Number
- NCT02722590
Halaven Post-Marketing Surveillance (PMS)
Completed
- Conditions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT02441764
Symbenda Post-Marketing Surveillance (PMS)
Completed
- Conditions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT02434484
- Locations
- π°π·
Eisai Trial Site #7, Busan, Korea, Republic of
π°π·Eisai Trial Site #8, Busan, Korea, Republic of
π°π·Eisai Trial Site #6, Daegu, Korea, Republic of
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
Completed
- Conditions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT02262975
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 2231
- Registration Number
- NCT02158910
Β© Copyright 2024. All Rights Reserved by MedPath